TY - JOUR
T1 - Estimating the likelihood of epilepsy from clinically noncontributory electroencephalograms using computational analysis
T2 - A retrospective, multisite case–control study
AU - Tait, Luke
AU - Staniaszek, Lydia E.
AU - Galizia, Elizabeth
AU - Martin-Lopez, David
AU - Walker, Matthew C.
AU - Azeez, Al Anzari Abdul
AU - Meiklejohn, Kay
AU - Allen, David
AU - Price, Chris
AU - Georgiou, Sophie
AU - Bagary, Manny
AU - Khalsa, Sakh
AU - Manfredonia, Francesco
AU - Tittensor, Phil
AU - Lawthom, Charlotte
AU - Howes, Benjamin B.
AU - Shankar, Rohit
AU - Terry, John R.
AU - Woldman, Wessel
N1 - Publisher Copyright:
© 2024 The Author(s). Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
PY - 2024/5/23
Y1 - 2024/5/23
N2 - Objective: This study was undertaken to validate a set of candidate biomarkers of seizure susceptibility in a retrospective, multisite case–control study, and to determine the robustness of these biomarkers derived from routinely collected electroencephalography (EEG) within a large cohort (both epilepsy and common alternative conditions such as nonepileptic attack disorder). Methods: The database consisted of 814 EEG recordings from 648 subjects, collected from eight National Health Service sites across the UK. Clinically noncontributory EEG recordings were identified by an experienced clinical scientist (N = 281; 152 alternative conditions, 129 epilepsy). Eight computational markers (spectral [n = 2], network-based [n = 4], and model-based [n = 2]) were calculated within each recording. Ensemble-based classifiers were developed using a two-tier cross-validation approach. We used standard regression methods to assess whether potential confounding variables (e.g., age, gender, treatment status, comorbidity) impacted model performance. Results: We found levels of balanced accuracy of 68% across the cohort with clinically noncontributory normal EEGs (sensitivity =61%, specificity =75%, positive predictive value =55%, negative predictive value =79%, diagnostic odds ratio =4.64, area under receiver operated characteristics curve =.72). Group level analysis found no evidence suggesting any of the potential confounding variables significantly impacted the overall performance. Significance: These results provide evidence that the set of biomarkers could provide additional value to clinical decision-making, providing the foundation for a decision support tool that could reduce diagnostic delay and misdiagnosis rates. Future work should therefore assess the change in diagnostic yield and time to diagnosis when utilizing these biomarkers in carefully designed prospective studies.
AB - Objective: This study was undertaken to validate a set of candidate biomarkers of seizure susceptibility in a retrospective, multisite case–control study, and to determine the robustness of these biomarkers derived from routinely collected electroencephalography (EEG) within a large cohort (both epilepsy and common alternative conditions such as nonepileptic attack disorder). Methods: The database consisted of 814 EEG recordings from 648 subjects, collected from eight National Health Service sites across the UK. Clinically noncontributory EEG recordings were identified by an experienced clinical scientist (N = 281; 152 alternative conditions, 129 epilepsy). Eight computational markers (spectral [n = 2], network-based [n = 4], and model-based [n = 2]) were calculated within each recording. Ensemble-based classifiers were developed using a two-tier cross-validation approach. We used standard regression methods to assess whether potential confounding variables (e.g., age, gender, treatment status, comorbidity) impacted model performance. Results: We found levels of balanced accuracy of 68% across the cohort with clinically noncontributory normal EEGs (sensitivity =61%, specificity =75%, positive predictive value =55%, negative predictive value =79%, diagnostic odds ratio =4.64, area under receiver operated characteristics curve =.72). Group level analysis found no evidence suggesting any of the potential confounding variables significantly impacted the overall performance. Significance: These results provide evidence that the set of biomarkers could provide additional value to clinical decision-making, providing the foundation for a decision support tool that could reduce diagnostic delay and misdiagnosis rates. Future work should therefore assess the change in diagnostic yield and time to diagnosis when utilizing these biomarkers in carefully designed prospective studies.
KW - biomarker
KW - case–control
KW - computational
KW - EEG
KW - network
UR - http://www.scopus.com/inward/record.url?scp=85194372446&partnerID=8YFLogxK
U2 - 10.1111/epi.18024
DO - 10.1111/epi.18024
M3 - Article
C2 - 38780578
AN - SCOPUS:85194372446
SN - 0013-9580
VL - 65
SP - 2459
EP - 2469
JO - Epilepsia
JF - Epilepsia
IS - 8
ER -